secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTELO BIOSCIENCES, INC. (ARTL)
CIK:        0001621221
Form:       8-K
Filed at:   2025-05-23T23:59:59+00:00
Accession:  0001640334-25-000935
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Artelo Biosciences notified by Nasdaq of equity deficiency; $652K vs $2.5M minimum
--------------------------------------------------------------------------------

- As of March 31, 2025, stockholders' equity was $652,000, below the $2.5M minimum required by Nasdaq Rule 5550(b)(1).
- Company has 45 days (until July 7, 2025) to submit a compliance plan to Nasdaq.
- If plan accepted, Nasdaq may grant up to 180 days (until Nov 18, 2025) to evidence compliance.
- No immediate impact on listing; common stock continues trading on Nasdaq pending review.
- Company evaluating options; no assurance that compliance plan will be accepted or delisting avoided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621221/000164033425000935/0001640334-25-000935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621221/000164033425000935/artl_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-25-000935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer